[House Report 111-631]
[From the U.S. Government Publishing Office]
111th Congress Report
HOUSE OF REPRESENTATIVES
2d Session 111-631
======================================================================
SCLERODERMA RESEARCH AND AWARENESS ACT OF 2010
_______
September 28, 2010.--Committed to the Committee of the Whole House on
the State of the Union and ordered to be printed
_______
Mr. Waxman, from the Committee on Energy and Commerce, submitted the
following
R E P O R T
[To accompany H.R. 2408]
[Including cost estimate of the Congressional Budget Office]
The Committee on Energy and Commerce, to whom was referred
the bill (H.R. 2408) to expand the research and awareness
activities of the National Institute of Arthritis and
Musculoskeletal and Skin Diseases and the Centers for Disease
Control and Prevention with respect to scleroderma, and for
other purposes, having considered the same, report favorably
thereon with an amendment and recommend that the bill as
amended do pass.
CONTENTS
Page
Amendment........................................................ 2
Purpose and Summary.............................................. 2
Background and Need for Legislation.............................. 2
Committee Consideration.......................................... 2
Committee Votes.................................................. 3
Committee Oversight Findings and Recommendations................. 3
New Budget Authority, Entitlement Authority, and Tax Expenditures 3
Statement of General Performance Goals and Objectives............ 3
Constitutional Authority Statement............................... 3
Earmarks and Tax and Tariff Benefits............................. 3
Federal Advisory Committee Statement............................. 4
Applicability of Law to the Legislative Branch................... 4
Federal Mandates Statement....................................... 4
Committee Cost Estimate.......................................... 4
Congressional Budget Office Cost Estimate........................ 4
Section-by-Section Analysis of the Legislation................... 5
Explanation of Amendments........................................ 6
Changes in Existing Law Made by the Bill, as Reported............ 6
Amendment
The amendment is as follows:
Strike all after the enacting clause and insert the
following:
SECTION 1. SHORT TITLE.
This Act may be cited as the ``Scleroderma Research and Awareness Act
of 2010''.
SEC. 2. NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN
DISEASES; SCLERODERMA RESEARCH EXPANSION.
Part B of title IV of the Public Health Service Act (42 U.S.C. 284 et
seq.) is amended by adding at the end the following:
``SEC. 409K. SCLERODERMA RESEARCH.
``The Director of NIH may expand, intensify, and coordinate the
activities of the National Institutes of Health with respect to
scleroderma, with particular emphasis on the following:
``(1) Research focused on the etiology of scleroderma and the
development of new treatment options.
``(2) Clinical research to evaluate new treatments options.
``(3) Basic research on the relationship between scleroderma
and secondary conditions such as pulmonary hypertension,
gastroparesis, Raynaud's phenomenon, Sjogren's Syndrome, and
other diseases as determined by the Director.''.
SEC. 3. PROMOTING PUBLIC AWARENESS OF SCLERODERMA.
Part P of title III of the Public Health Service Act (42 U.S.C. 280g
et seq.) is amended by adding at the end the following:
``SEC. 399V-5. PROMOTING PUBLIC AWARENESS OF SCLERODERMA.
``The Secretary may carry out an educational campaign to increase
public awareness of scleroderma. Print, video, and Web-based materials
distributed through this campaign may include--
``(1) basic information on scleroderma and its symptoms; and
``(2) information on--
``(A) the incidence and prevalence of scleroderma;
``(B) diseases and conditions affiliated with
scleroderma; or
``(C) the importance of early diagnosis and treatment
of scleroderma.''.
Purpose and Summary
H.R. 2408, the ``Scleroderma Research and Awareness Act of
2010'', was introduced by Rep. Lois Capps (D-CA) on May 14,
2010, and referred to the Committee on Energy and Commerce.
The goal of H.R. 2408 is to address the need for research
on scleroderma, a chronic systemic autoimmune disease.
Background and Need for Legislation
Scleroderma is a chronic connective tissue disease that can
involve changes in the skin, blood vessels, muscles, and
internal organs. An estimated 300,000 people in the United
States have scleroderma. The exact cause or causes of
scleroderma are still unknown and there is no cure,
necessitating more research into and awareness of this disease.
Committee Consideration
H.R. 2408, the ``Scleroderma Research and Awareness Act of
2010'', was introduced by Mrs. Capps of California on May 14,
2010, and referred to the Committee on Energy and Commerce. The
bill was subsequently referred to the Subcommittee on Health on
May 15, 2010. On September 15, 2010, the Subcommittee held a
legislative hearing on the bill. The Subcommittee met in open
markup session to consider H.R. 2408 on September 16, 2010. An
amendment in the nature of a substitute (manager's amendment)
by Mrs. Capps of California was adopted by a voice vote.
Subsequently, H.R. 2408 was favorably forwarded to the full
Committee, amended, by a voice vote.
On September 23, 2010, the Committee on Energy and Commerce
met in open markup session and considered H.R. 2408 as approved
by the Subcommittee on Health. There were no amendments offered
in full Committee and subsequently the Committee ordered H.R.
2408 favorably reported to the House, as amended by the
Subcommittee on Health, by a voice vote.
Committee Votes
Clause 3(b) of rule XIII of the Rules of the House of
Representatives requires the Committee to list each record vote
on the motion to report legislation and amendments thereto. A
motion by Mr. Pallone ordering H.R. 2408 reported to the House,
as amended, was approved by a voice vote. There were no record
votes taken during consideration of this bill.
Committee Oversight Findings and Recommendations
In compliance with clause 3(c)(1) of rule XIII and clause
(2)(b)(1) of rule X of the Rules of the House of
Representatives, the oversight findings and recommendations of
the Committee are reflected in the descriptive portions of this
report, including the finding that there is a need for
increased research on and awareness of scleroderma.
New Budget Authority, Entitlement Authority, and Tax Expenditures
Regarding compliance with clause 3(c)(2) of rule XIII of
the Rules of the House of Representatives, the Committee finds
that H.R. 2408 would result in no new budget authority,
entitlement authority, or tax expenditures or revenues.
Statement of General Performance Goals and Objectives
In accordance with clause 3(c)(4) of rule XIII of the Rules
of the House of Representatives, the performance goals and
objectives of the Committee are reflected in the descriptive
portions of this report, including the goal of increasing
research on and awareness of scleroderma.
Constitutional Authority Statement
Pursuant to clause 3(d)(1) of rule XIII of the Rules of the
House of Representatives, the Committee finds that the
constitutional authority for H.R. 2408 is provided under
article I, section 8, clauses 3 and 18 of the Constitution of
the United States.
Earmarks and Tax and Tariff Benefits
H.R. 2408 does not contain any congressional earmarks,
limited tax benefits, or limited tariff benefits as defined in
clause 9 of rule XXI of the Rules of the House of
Representatives.
Federal Advisory Committee Statement
The Committee finds that the legislation does not establish
or authorize the establishment of an advisory committee within
the definition of 5 U.S.C. App., section 5(b) of the Federal
Advisory Committee Act.
Applicability of Law to the Legislative Branch
Section 102(b)(3) of Public Law 104-1 requires a
description of the application of this bill to the legislative
branch where the bill relates to terms and conditions of
employment or access to public services and accommodations.
H.R. 2408 contains no such provisions.
Federal Mandates Statement
Section 423 of the Congressional Budget and Impoundment
Control Act of 1974 (as amended by section 101(a)(2) of the
Unfunded Mandates Reform Act, Public Law 104-4) requires a
statement on whether the provisions of the report include
unfunded mandates. In compliance with this requirement the
Committee adopts as its own the analysis of federal mandates
prepared by the Director of the Congressional Budget Office
regarding H.R. 2408.
Committee Cost Estimate
Pursuant to clause 3(d)(2) of rule XIII of the Rules of the
House of Representatives, the Committee adopts as its own the
cost estimate of H.R. 2408 prepared by the Director of the
Congressional Budget Office pursuant to section 402 of the
Congressional Budget Act of 1974.
Congressional Budget Office Cost Estimate
With respect to the requirements of clause 3(c)(3) of rule
XIII of the Rules of the House of Representatives and section
402 of the Congressional Budget Act of 1974, the Committee has
received the following cost estimate for H.R. 2408 from the
Director of Congressional Budget Office:
September 24, 2010.
Hon. Henry A. Waxman,
Chairman, Committee on Energy and Commerce,
House of Representatives, Washington, DC.
Dear Mr. Chairman: The Congressional Budget Office has
prepared the enclosed cost estimate for H.R. 2408, the
Scleroderma Research and Awareness Act of 2010.
If you wish further details on this estimate, we will be
pleased to provide them. The CBO staff contacts are Jamease
Kowalczyk and Stephanie Cameron.
Sincerely,
Douglas W. Elmendorf.
Enclosure.
H.R. 2408--Scleroderma Research and Awareness Act of 2010
Summary: H.R. 2408 would encourage the Director of the
National Institutes of Health (NIH) to expand, intensify, and
coordinate scleroderma research activities. It also would
authorize the Secretary of Health and Human Services (HHS) to
conduct an educational campaign to increase public awareness of
scleroderma. CBO estimates that implementing H.R. 2408 would
cost $12 million over the 2011-2015 period, assuming
appropriation of the necessary amounts. Enacting H.R. 2408
would not affect direct spending or revenues; therefore, pay-
as-you-go procedures do not apply.
H.R. 2408 contains no intergovernmental or private-sector
mandates as defined in the Unfunded Mandates Reform Act (UMRA).
Estimated cost to the Federal Government: The estimated
budgetary impact of H.R. 2408 is shown in the following table.
The costs of this legislation fall within budget function 550
(health).
----------------------------------------------------------------------------------------------------------------
By fiscal year, in millions of dollars--
-----------------------------------------------------------
2011-
2011 2012 2013 2014 2015 2015
----------------------------------------------------------------------------------------------------------------
CHANGES IN SPENDING SUBJECT TO APPROPRIATION
Estimated Authorization Level....................... 3 5 4 0 0 12
Estimated Outlays................................... 1 3 4 3 1 12
----------------------------------------------------------------------------------------------------------------
Basis of estimate: For this estimate, CBO assumes that H.R.
2408 will be enacted near the beginning of fiscal year 2011 and
that the necessary amounts will be appropriated each year. The
bill would encourage the Director of NIH to expand, intensify,
and coordinate scleroderma-related activities with a focus on
the etiology and development of new treatments for scleroderma,
clinical research for new treatment options, and basic research
on the relationship between scleroderma and secondary
conditions. Currently, those activities are underway at NIH, so
implementing those provisions would have no budgetary effect.
H.R. 2408 also would authorize the Secretary of HHS to
conduct an educational campaign through print, video, and Web-
based materials to increase public awareness of scleroderma.
Based on spending by the Centers for Disease Control and
Prevention for similar activities, CBO estimates that
implementing H.R. 2408 would cost $1 million in 2011 and $12
million over the 2011-2015 period.
Pay-As-You-Go considerations: None.
Intergovernmental and private-sector impact: H.R. 2408
contains no intergovernmental or private-sector mandates as
defined in UMRA and would impose no costs on state, local, or
tribal governments.
Estimate prepared by: Federal costs: Stephanie Cameron and
Jamease Kowalczyk; Impact on state, local, and tribal
governments: Lisa Ramirez-Branum; Impact on the private sector:
Jimmy Jin.
Estimate approved by: Holly Harvey, Deputy Assistant
Director for Budget Analysis.
Section-by-Section Analysis of the Legislation
Section 1. Short title
Section 1 designates that the Act may be cited as the
``Scleroderma Research and Awareness Act of 2010''.
Section 2. National Institute of Arthritis and Musculoskeletal and Skin
Diseases; Scleroderma research expansion
Section 2 amends the Public Health Services Act (PHSA) to
authorize the Director of the National Institutes of Health
(NIH) to expand, intensify, and coordinate the activities of
NIH with respect to scleroderma.
Section 3. Promoting public awareness of scleroderma
Section 3 amends the PHSA to authorize the Secretary of
Health and Human Services to carry out an educational campaign
to increase public awareness of scleroderma.
Explanation of Amendment
During the Subcommittee on Health markup of H.R. 2408, Mrs.
Capps of California offered an amendment in the nature of a
substitute (manager), which was adopted by a voice vote. The
substance of the substitute amendment is reflected in the
section-by-section analysis contained in this report.
Changes in Existing Law Made by the Bill, as Reported
In compliance with clause 3(e) of rule XIII of the Rules of
the House of Representatives, changes in existing law made by
the bill, as reported, are shown as follows (new matter is
printed in italics and existing law in which no change is
proposed is shown in roman):
PUBLIC HEALTH SERVICE ACT
* * * * * * *
TITLE III--GENERAL POWERS AND DUTIES OF PUBLIC HEALTH SERVICE
* * * * * * *
PART P--ADDITIONAL PROGRAMS
* * * * * * *
SEC. 399V-5. PROMOTING PUBLIC AWARENESS OF SCLERODERMA.
The Secretary may carry out an educational campaign to
increase public awareness of scleroderma. Print, video, and
Web-based materials distributed through this campaign may
include--
(1) basic information on scleroderma and its
symptoms; and
(2) information on--
(A) the incidence and prevalence of
scleroderma;
(B) diseases and conditions affiliated with
scleroderma; or
(C) the importance of early diagnosis and
treatment of scleroderma.
* * * * * * *
TITLE IV--NATIONAL RESEARCH INSTITUTES
* * * * * * *
Part B--General Provisions Respecting National Research Institutes
* * * * * * *
SEC. 409K. SCLERODERMA RESEARCH.
The Director of NIH may expand, intensify, and coordinate the
activities of the National Institutes of Health with respect to
scleroderma, with particular emphasis on the following:
(1) Research focused on the etiology of scleroderma
and the development of new treatment options.
(2) Clinical research to evaluate new treatments
options.
(3) Basic research on the relationship between
scleroderma and secondary conditions such as pulmonary
hypertension, gastroparesis, Raynaud's phenomenon,
Sjogren's Syndrome, and other diseases as determined by
the Director.
* * * * * * *